<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050855</url>
  </required_header>
  <id_info>
    <org_study_id>08-005658</org_study_id>
    <secondary_id>CHP 894</secondary_id>
    <nct_id>NCT01050855</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders</brief_title>
  <acronym>RIC</acronym>
  <official_title>Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II pilot study to evaluate engraftment and toxicity of patients with&#xD;
      non-malignant diseases using a reduced intensity conditioning regimen in the setting of&#xD;
      allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be&#xD;
      acceptable as a stem cell source.&#xD;
&#xD;
      Recently, reduced intensity conditioning (RIC) regimens have been used for both adult&#xD;
      patients with leukemias and pediatric patients with non-malignant diseases. These regimens&#xD;
      are better tolerated, resulting in less transplant related morbidity and mortality. Stable&#xD;
      mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure&#xD;
      patients with non-malignant diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two conditioning regimens in this protocol for children &gt;6 months. Alemtuzumab&#xD;
      (Campath), Fludarabine and Melphalan are used. The regimens differ by the timing and dosing&#xD;
      of Alemtuzumab (Campath). The two timings are distal and intermediate.&#xD;
&#xD;
        -  Distal campath is initiated 22 days prior to the allogeneic transplant.&#xD;
&#xD;
        -  Intermediate campath is initiated 14 days prior to allogeneic transplant.&#xD;
&#xD;
      The conditioning regimen for children with immunodeficiencies &lt;6 months omits melphalan, and&#xD;
      substitutes two days of busulfan. This regimen is successfully used in the UK, and has been&#xD;
      successful in a 3 month old infant at the Children's Hospital of Philadelphia (CHOP) who&#xD;
      engrafted with a haploidentical donor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment</measure>
    <time_frame>Post Transplant -100 days</time_frame>
    <description>engraftment of patients with non-malignant disorders will be evaluated using a reduced-intensity conditioning regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Event free survival will be evaluated by the time interval to either the primary or late graft failure, disease recurrence or death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non Malignant Diseases</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Hemoglobinopathies</condition>
  <arm_group>
    <arm_group_label>RIC: Distal Campath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day Treatment&#xD;
Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) (subcutaneously) over 2 hours&#xD;
Day - 21 to-19 Alemtuzumab IV/ SQ (subcutaneously)&#xD;
Day - 7 to -3 Readmission to hospital Fludarabine IV&#xD;
Day - 2 Melphalan IV&#xD;
Day - 1 Begin cyclosporine infusion&#xD;
Day 0 Transplant: Bone marrow or cord blood infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIC:Intermediate Campath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day Treatment&#xD;
Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)&#xD;
Day - 7 to -3 Fludarabine IV&#xD;
Day - 2 Melphalan 140 mg/m2 IV&#xD;
Day - 1 Cyclosporine infusion starts&#xD;
Day 0 Transplant: Bone marrow or cord blood infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIC: Mini Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day Treatment&#xD;
Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)&#xD;
Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)&#xD;
Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV&#xD;
Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV&#xD;
Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV&#xD;
Day - 3 Fludarabine IV&#xD;
Day - 2 Fludarabine IV Cyclosporine infusion&#xD;
Day - 1 Rest&#xD;
Day 0 Transplant: Bone marrow or cord blood infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIC: Distal Campath</intervention_name>
    <description>Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)</description>
    <arm_group_label>RIC: Distal Campath</arm_group_label>
    <other_name>Reduced Intensity Conditioning Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIC:Intermediate Campath</intervention_name>
    <description>Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)</description>
    <arm_group_label>RIC:Intermediate Campath</arm_group_label>
    <other_name>Reduced Intensity Conditioning Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIC: Mini Busulfan</intervention_name>
    <description>Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)</description>
    <arm_group_label>RIC: Mini Busulfan</arm_group_label>
    <other_name>Reduced Intensity Conditioning Regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;6 months- 25 years&#xD;
&#xD;
          2. Diseases eligible for Distal Alemtuzumab:&#xD;
&#xD;
               -  Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome&#xD;
&#xD;
               -  Sickle cell disease&#xD;
&#xD;
               -  Thalassemia major&#xD;
&#xD;
               -  Bone marrow failure&#xD;
&#xD;
          3. Diseases eligible for Intermediate Alemtuzumab&#xD;
&#xD;
               -  Hemophagocytic lymphohistiocytosis other macrophage activation syndromes, severe&#xD;
                  Langerhans histiocytosis&#xD;
&#xD;
               -  Severe combined immune deficiency, adenosine deaminase deficiency, common&#xD;
                  variable immunodeficiency&#xD;
&#xD;
               -  Wiskott-Aldrich syndrome&#xD;
&#xD;
          4. Organ criteria:&#xD;
&#xD;
               -  Cardiac: Echocardiogram shortening fraction &gt;27%&#xD;
&#xD;
               -  Renal: Serum creatinine less than 1.5 times the upper limit of normal for age&#xD;
&#xD;
               -  Hepatic: liver function tests must be less than 5 times the upper limit of normal&#xD;
&#xD;
          5. No active infections&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        1. Uncontrolled bacterial, fungal or viral infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J Olson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara McGlynn</last_name>
    <phone>215-590-1303</phone>
    <email>mcglynn@chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Hankins, RN</last_name>
    <phone>215-590-5168</phone>
    <email>hankinsp@chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara McGlynn</last_name>
      <phone>215-590-1303</phone>
      <email>mcglynn@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Hankins, RN</last_name>
      <phone>215 590-5168</phone>
      <email>hankinsp@chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nancy J Bunin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-malignant diseases</keyword>
  <keyword>Immune deficiencies</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Reduced Intensity Conditioning(RIC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

